<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04079049</url>
  </required_header>
  <id_info>
    <org_study_id>BreCLIM-2018-116-31M</org_study_id>
    <nct_id>NCT04079049</nct_id>
  </id_info>
  <brief_title>BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases</brief_title>
  <acronym>BreCLIM-2</acronym>
  <official_title>Breast Cancer Liver Metastases-2 - A Multicentre Randomized Clinical Trial Investigating Local Treatment for Breast Cancer Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the second most common cancer in Sweden with an incidence of 8000 per year.
      The role of surgery for distant breast cancer metastasis beyond local lymph nodes remains
      controversial even though some reports suggest there might be a survival benefit from
      resection of oligometastases in the liver.

      The purpose of this multicentre randomized clinical trial is to evaluate local treatment for
      breast cancer liver metastases, compared to systemic oncological treatment only. The primary
      endpoint is time to death from any cause, which will be compared using cox proportional
      hazard regression. The secondary endpoints are three years survival, progression-free
      survival, median overall survival and quality of life. The aim is also to evaluate overall
      safety and predictive factors for survival during oncological and surgical treatment. The
      overall purpose is to ameliorate treatment for advanced breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Three years after randomization</time_frame>
    <description>Time to death from any cause</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Surgical intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical and oncological treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oncological treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical intervention</intervention_name>
    <description>Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment</description>
    <arm_group_label>Surgical intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Oncological treatment in control group</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  &gt;18 years old

          -  ECOG 0-1

          -  Breast cancer history

          -  Breast cancer liver metastasis verified by biopsy

          -  Patient amendable for liver surgery and pre- and postoperative oncological treatment

          -  1-4 liver metastasis amendable to surgery with functional liver remnant volume &gt;30%

          -  Liver metastasis (and skeletal metastasis) stable or responding to preoperative
             oncological treatment

        Exclusion Criteria:

          -  Non-skeletal extrahepatic disease

          -  Non-resected primary tumour

          -  Pregnancy

          -  Progression of disease upon oncological treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskar Hemmingsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oskar Hemmingsson, MD, PhD</last_name>
    <phone>0046707197548</phone>
    <email>oskar.hemmingsson@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Malin Sund, MD, PhD</last_name>
    <phone>0046907850000</phone>
    <email>malin.sund@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oskar Hemmingsson, MD, PhD</last_name>
      <phone>0046 707197548</phone>
      <email>oskar.hemmingsson@umu.se</email>
    </contact>
    <contact_backup>
      <last_name>Anne Andersson, MD, PhD</last_name>
      <phone>0046 907850000</phone>
      <email>anne.andersson@umu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

